Pharming Group Nv (PHAR) has disclosed a new risk, in the Manufacturing category.
Pharming Group Nv faces significant business risk following the U.S. approval of its drug Joenja. As the drug enters wider use, any emerging safety or efficacy concerns from comprehensive market surveillance could compel regulatory actions such as label modifications, administration changes, or even product recalls. These potential outcomes may not only hinder Joenja’s market acceptance but also materially impact Pharming Group Nv’s operations and financial stability.
Overall, Wall Street has a Moderate Buy consensus rating on PHAR stock based on 1 Buy.
To learn more about Pharming Group Nv’s risk factors, click here.
